Karyopharm Therapeutics Inc.
KPTI
$8.38
-$0.17-1.99%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 146.07M | 142.53M | 137.27M | 142.13M | 145.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 146.07M | 142.53M | 137.27M | 142.13M | 145.24M |
| Cost of Revenue | 131.57M | 137.05M | 141.83M | 147.82M | 149.24M |
| Gross Profit | 14.50M | 5.48M | -4.56M | -5.70M | -4.00M |
| SG&A Expenses | 105.21M | 109.63M | 110.65M | 113.24M | 115.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 236.77M | 246.67M | 252.48M | 261.07M | 264.68M |
| Operating Income | -90.71M | -104.14M | -115.21M | -118.94M | -119.44M |
| Income Before Tax | -196.00M | -124.62M | -123.57M | -62.50M | -76.37M |
| Income Tax Expenses | 43.00K | 1.00K | -5.00K | 22.00K | 57.00K |
| Earnings from Continuing Operations | -196.04 | -124.62 | -123.57 | -62.52 | -76.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -196.04M | -124.62M | -123.57M | -62.52M | -76.42M |
| EBIT | -90.71M | -104.14M | -115.21M | -118.94M | -119.44M |
| EBITDA | -90.41M | -103.79M | -114.89M | -118.61M | -119.10M |
| EPS Basic | -16.62 | -14.58 | -14.61 | -8.02 | -9.39 |
| Normalized Basic EPS | -8.21 | -9.11 | -9.13 | -8.05 | -9.34 |
| EPS Diluted | -16.62 | -14.58 | -14.61 | -13.26 | -14.62 |
| Normalized Diluted EPS | -8.21 | -9.11 | -9.13 | -7.70 | -9.00 |
| Average Basic Shares Outstanding | 43.66M | 34.15M | 33.82M | 33.27M | 32.50M |
| Average Diluted Shares Outstanding | 43.66M | 34.15M | 33.82M | 35.49M | 34.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |